FDA Approves First mRNA Flu Vaccine for Adults 50+
mRNA flu vaccine mFLUSIVA received FDA approval August 5, 2026 for adults 50 and older, marking the first influenza shot in US history using messenger RNA technology.
What Happened
The Food and Drug Administration approved the U.S.' first flu shot that uses mRNA technology: mFlusiva, from drugmaker Moderna. The FDA granted approval for two age groups, adults 50 to 65 and adults 65 and up, on the condition that Moderna run an additional clinical trial in the older group.
Why This Matters
In a late-stage trial, mFlusiva was found to be about 27% more effective than a standard flu shot. A vaccine that does not have to use chickens and eggs will benefit public health enormously and will allow rapid adjustment to rapidly emerging new flu strains. Moderna expects to have some doses of the vaccine available for administration in advance of the coming flu season.
For Expats and Newcomers
If you or family members are 50 or older, you'll want to know about this new option as flu season approaches this fall. The mRNA approach means faster vaccine development if new strains emerge — relevant if you're considering travel to or from the US. Adverse reactions consistent with mRNA vaccines, such as fatigue, joint pain and muscle aches, were recorded in the trial. Discuss with your doctor whether this updated vaccine is right for your health situation.
Sources
MyHAbroad is an independent app and is not affiliated with, endorsed by, or representing any government or public authority. This is general information only — not legal, tax, medical, or financial advice. Always verify with the official source before acting:
